Systemic Administration of the Immunophilin Ligand GPI 1046 in MPTP-Treated Monkeys
- 31 March 2001
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 168 (1), 171-182
- https://doi.org/10.1006/exnr.2000.7592
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeysJournal of Comparative Neurology, 1998
- MPTP-Induced Hemiparkinsonism in Nonhuman Primates 6–8 Years after a Single Unilateral Intracarotid DoseExperimental Neurology, 1998
- Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson diseaseProceedings of the National Academy of Sciences, 1997
- Dopaminergic Neurons Protected from Degeneration by GDNF Gene TherapyScience, 1997
- A consideration of neural counting methodsTrends in Neurosciences, 1992
- Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regionsNeuroscience, 1989
- Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeysNeuroscience, 1986
- Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)Life Sciences, 1986
- A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proceedings of the National Academy of Sciences, 1983
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979